Author/Authors :
Ghoreishi, Masoumeh Babol University of Medical Sciences - Babol, Iran , Najdian, Atena Department of Radiopharmacy - Faculty of Pharmacy - Tehran University of Medical Sciences - Tehran, Iran , Yadegari, Sina Department of Radiopharmacy - Faculty of Pharmacy - Tehran University of Medical Sciences - Tehran, Iran , Seyedhamzeh, Mohammad Department of Radiopharmacy - Faculty of Pharmacy - Tehran University of Medical Sciences - Tehran, Iran , Etemadzade, Maziyar Department of Biology - Tehran Medical Branch - Islamic Azad University - Tehran, Iran , Mirzaei, Mehdi Iran Ministry of Health and Medical Education - Deputy Ministry for Education - Tehran, Iran , Hadadian, Shahin Nanobiotechnology Department - Pasteur Institute of Iran - Tehran, Iran , Alikhani, Zahra Department of Microbiology - Kerman Islamic Azad University - Kerman, Iran , Shafiee Ardestani, Mehdi Department of Radiopharmacy - Faculty of Pharmacy - Tehran University of Medical Sciences - Tehran, Iran
Abstract :
Even today, technetium-99m is a radionuclide choice for diagnostic in nuclear medicine. The unique chemical and physical
properties of technetium-99m make it suitable as an available radionuclide in many centers. In this study, we examined the
potential of CQD as a reducing agent in the MDP kit. Citric acid-derived CQD was synthesized and confirmed by FT-IR, TEM,
UV-Vis, XPS, and surface analysis. No cytotoxicity was observed by the MTT assay. They were reducing properties of the CQD
confirmed by fluorescence microscopy. The MDP kit is prepared by evaluating different parameters that affect the radiolabeling
yield, including ligand, time, and CQD. The optimum amount of each parameter is obtained by Box–Behnken software. Finally,
fluorescent spectroscopy, SPECT imaging, and biodistribution study showed that CQD reduces technetium-99m. Accumulation
of radiotracer in the femur showed that CQD could be used in a radiopharmaceutical kit.
Keywords :
Carbon , Chloride , Radiopharmaceutical , MRI
